WO2024208816 - BLOOD-BRAIN BARRIER CROSSING ANTIBODIES
National phase entry:
Publication Number
WO/2024/208816
Publication Date
10.10.2024
International Application No.
PCT/EP2024/058918
International Filing Date
02.04.2024
Title **
[English]
BLOOD-BRAIN BARRIER CROSSING ANTIBODIES
[French]
ANTICORPS TRAVERSANT LA BARRIÈRE HÉMATO-ENCÉPHALIQUE
Applicants **
VIB VZW
Suzanne Tassierstraat 1
9052 Gent, BE
KATHOLIEKE UNIVERSITEIT LEUVEN
K.U.LEUVEN R&D
Waaistraat 6 - bus 5105
3000 Leuven, BE
Inventors
DE STROOPER, Bart
c/o VIB-KU Leuven Center for Brain & Disease Research
Herestraat 49
3000 Leuven, BE
DOMBRECHT, Bruno
c/o VIB vzw
Suzanne Tassierstraat 1
9052 Gent, BE
DEWILDE, Maarten
c/o KU Leuven
Laboratory for Therapeutic and Diagnostic Antibodies
Herestraat 49
3000 Leuven, BE
JASPERS, Tom
c/o KU Leuven
Laboratory for Therapeutic and Diagnostic Antibodies
Herestraat 49
3000 Leuven, BE
RUÉ, Laura
c/o KU Leuven
Laboratory for Therapeutic and Diagnostic Antibodies
Herestraat 49
3000 Leuven, BE
Priority Data
23166341.0
03.04.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1445 | |
| EPO | Filing, Examination | 6286 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3835 |
Total: 12672 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to antibodies or antibody fragments binding to the human and non-humane primate transferrin receptor. The antibodies herein described can be used as agents to deliver pharmaceutical compounds in or across cells in the process of receptor mediated endocytosis and/or transcytosis. As the transferrin receptor is also present at the blood brain barrier endothelial cells, one aspect of the invention provides means and methods to increase the delivery of pharmaceutical compounds to the central nervous system.[French]
La présente invention concerne des anticorps ou des fragments d'anticorps se liant au récepteur de transferrine de primate humain et non humain. Les anticorps selon l'invention peuvent être utilisés en tant qu'agents d'administration de composés pharmaceutiques dans ou à travers des cellules dans le processus d'endocytose et/ou de transcytose à médiation par un récepteur. Comme le récepteur de transferrine est également présent au niveau des cellules endothéliales de la barrière hémato-encéphalique, un aspect de l'invention concerne des moyens et des méthodes permettant d'augmenter l'administration de composés pharmaceutiques au système nerveux central.